

Abstract

The present invention relates to liquid formulations of human interferon- β . The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon- β in solution while retaining the molecular integrity.

sh/ANM/17150PEP 17.09.98 10:32